Leading the fight against cancer with over 40 new molecules
For more information about molecules in early and late-stage development at Genentech and Roche, please click on the headings below.
SECTIONS
- All
- Breast
- Gastrointestinal
- Hematologic
- Lung
- Other tumor types
- Ovarian
- Solid Tumors
- Developed by Roche Pharma Research & Early Development (pRED)
- Developed by Genentech Research & Early Development (gRED)
- Developed by Pharma Medicines (pMED)
Lung
Phase I
-
Antibody-drug conjugate (RG7599)j Non-small cell lung cancer
Phase II
-
Onartuzumab (MetMAb, anti-Met MAb, RG3638) Non-squamous and squamous cell, non-small cell lung cancer
-
Anti-EGFR/ADCC MAb (GA201, RG7160) Non-small cell lung cancer
-
Anti-EGFL7 MAb (MEGF0444A, RG7414) First-line metastatic non-small cell lung cancer
Phase III
-
Onartuzumab (MetMAb, anti-Met MAb, RG3638) Metastatic non-small cell lung cancer
Solid Tumors
Phase I
-
Anti-CD44 MAb (RG7356)o Solid tumors
-
Anti-PlGF MAb (RG7334)p Solid tumors
-
Anti-TWEAK MAb (RG7212) Solid tumors
-
MEK inhibitor CIF (RG7167)q Solid tumors
-
Anti-CSF-1R MAb (RG7155) Solid tumors
-
Anti-HER3/ADCC MAb (RG7116) Solid tumors
-
MDM2 antagonist (RG7112) Solid tumors
-
MDM2 antagonist (RG7388) Solid tumors
-
MEK inhibitor CKI27 (RG7304)r Solid tumors
-
Akt inhibitor (GDC-0068, RG7440)s Solid tumors
-
Anti-angiogenic MAb (MINT1526A, RG7594) Solid tumors
-
ChK1 inhibitor (GDC-0425, RG7602)h Solid tumors
-
MEK inhibitor (GDC-0973, RG7420) Solid tumors
-
MEK inhibitor (GDC-0623, RG7421)t Solid tumors
-
PD-L1 MAb (RG7446) Solid tumors
-
PI3K inhibitor (GDC-0032, RG7604) Solid tumors
Phase II
-
PI3K inhibitor (GDC-0941, RG7321) Solid tumors
-
PI3K/mTOR inhibitor (GDC-0980, RG7422) Solid tumors
Gastrointestinal
Phase I
-
Antibody-drug conjugate (RG7600)b Pancreatic cancer
Phase II
-
Anti-EGFR/ADCC MAb (GA201, RG7160) Colorectal cancer
-
Anti-glypican-3 MAb (GC33, RG7686)c Hepatocellular carcinoma
-
Onartuzumab (MetMAb, anti-Met MAb, RG3638) Metastatic colorectal cancer
-
Anti-EGFL7 MAb (MEGF0444A, RG7414) First-line metastatic colorectal cancer
Other tumor types
Phase I
-
BRAF inhibitor (RG7256)k BRAF-mutated solid tumors
-
Antibody-drug conjugate (RG7636)l Metastatic melanoma
-
Antibody-drug conjugate (DSTP3086S, RG7450)m Prostate cancer
Phase II
-
Anti-HER3/EGFR MAb (MEHD7945A, RG7597) Metastatic epithelial tumors
Hematologic
Phase I
-
MDM2 antagonist (RG7112) Hematologic malignancies
-
MDM2 antagonist (RG7388) Hematologic malignancies
-
Antibody-drug conjugate (DCDS4501A, RG7596)d Hematologic malignancies
-
Antibody-drug conjugate (RG7598)e Multiple myeloma
-
Anti-CD22 antibody-drug conjugate (DCDT2980S,
RG7593)fHematologic malignancies
-
Bcl-2 inhibitor (ABT-199, GDC-0199, RG7601)g Relapsed or refractory CLL,* relapsed or refractory NHL†
-
ChK1 inhibitor (GDC-0425, RG7602)h Lymphoma
Phase II
-
PI3K/mTOR inhibitor (GDC-0980, RG7422) Hematologic malignancies
Ovarian
Phase I
-
Antibody-drug conjugate (RG7458)n Ovarian cancer
-
Antibody-drug conjugate (RG7599)j Ovarian cancer
-
Antibody-drug conjugate (RG7600)b Ovarian cancer
*Chronic lymphocytic leukemia.
† Non-Hodgkin's lymphoma.
‡ Diffuse large B-cell lymphoma
a RG3502 (trastuzumab emtansine): developed in collaboration with ImmunoGen.
b RG7600 (ADC): developed in collaboration with Seattle Genetics.
c RG7686 (anti-glypican-3): developed in collaboration with Chugai.
d RG7596 (ADC): developed in collaboration with Seattle Genetics.
e RG7598 (ADC): developed in collaboration with Seattle Genetics.
f RG7593 (ADC): developed in collaboration with Seattle Genetics.
g RG7601 (GDC-0199): developed in collaboration with Abbott and WEHI.
h RG7602 (GDC-0425): developed in collaboration with Array BioPharma.
i RG7159 (obinutuzumab): developed in collaboration with Biogen Idec.
j RG7599 (ADC): developed in collaboration with Seattle Genetics.
k RG7256 (BRAF): developed in collaboration with Plexxikon, a member of Daiichi Sankyo Group.
l RG7636 (ADC): developed in collaboration with Seattle Genetics.
m RG7450 (ADC): developed in collaboration with Seattle Genetics.
n RG7458 (ADC): developed in collaboration with Seattle Genetics.
o RG7356 (anti-CD44): developed in collaboration with Arius.
p RG7334 (anti-PlGF): developed in collaboration with ThromboGenics/BioInvent.
q RG7167 (CIF/MEK): developed in collaboration with Chugai.
r RG7304 (Raf/MEK CKI27): developed in collaboration with Chugai.
s RG7440 (GDC-0068): developed in collaboration with Array BioPharma.
t RG7421 (GDC-0623): developed in collaboration with Exelixis.